NEW YORK (GenomeWeb) — Invivoscribe announced today that it has submitted its LeukoStrat CDx FLT3 Mutation Assay to Japanese regulators as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.
NEW YORK (GenomeWeb) — Invivoscribe announced today that it has submitted its LeukoStrat CDx FLT3 Mutation Assay to Japanese regulators as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.